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The mouse IGF-I gene contains six exons, and exon 1 and exon 2 gene are considered to be leader 
exons. The regulatory mechanism of alternative usage of the leader exons is unclear in mice. The 
present study was aimed at clarifying changes in class 1 (derived from exon 1) and class 2 (derived 
from exon 2) IGF-I mRNA expression in mice under various conditions. Both class 1 and class 2 
IGF-I mRNAs were expressed in the mouse uterus, liver and kidney, and class 1 IGF-I mRNA was 
the major transcript in all organs studied. In the uterus, both class 1 and class 2 IGF-I mRNA 
expression changed markedly during the estrous cycle, with the highest level at proestrus, but in 
the liver and kidney there were no significant changes in IGF-I mRNA expression during the estrous 
cycle. Estrogen treatment increased both class 1 and class 2 IGF-I mRNA levels in the uterus of 
ovariectomized mice, but class 1 mRNA expression increased more in response to estrogen treat-
ment than class 2 mRNA expression. These findings suggest that estrogen stimulates IGF-I gene 
expression in uterine cells, and that a promoter involved in transcription of class 1 IGF-I mRNA is 
more responsive to estrogen. In conclusion, the present study revealed that two leader exons of 
mouse IGF-I gene are used in the uterus, liver and kidney. IGF-I mRNA levels of both classes 
changed during the estrous cycle in the uterus, but not in the liver or kidney. Estrogen increased 
IGF-I mRNA levels of both classes in the uterus.
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INTRODUCTION
Insulin-like growth factor-I (IGF-I) is an integral compo-
nent of multiple systems controlling somatic growth, and 
regulates cell-cycle progression and apoptosis (LeRoith et 
al., 1995; Resnicoff et al., 1995; Jung et al., 1996; Parrizas 
and LeRoith, 1997). IGF-I, a basic peptide of 70 amino acids 
is synthesized in precursor forms and processed post-trans-
lationally. The mammalian IGF-I gene consists of six exons 
(Rotwein et al., 1986; Shimatsu and Rotwein, 1987; Kamai
et al., 1996). Exons 1 and 2 are considered to be leader 
exons, and encode distinct 5’-flanking untranslated regions 
and signal peptide sequences. Alternative usage of the two 
leader exons results in the generation of two types of IGF-I 
transcripts (class 1 and class 2). Exon 1 is spliced to exon 
3 to produce class 1 IGF-I mRNA, and exon 2 is spliced to 
exon 3 to produce class 2 IGF-I mRNA (Lowe et al., 1987; 
Adamo et al., 1989, 1991; Jansen et al., 1991). Exon 3 
encodes the remainder of the signal peptide and the first 
part of the B domain of the IGF-I peptide. Exon 4 encodes 
the remainder of the B, C, A and D domains, as well as the 
first part of the E peptide moiety of the prohormone. Exon 5 
is an alternatively spliced cassette exon of 52 base pairs 
(bp).
In the human IGF-I gene two alternatively used promot-
ers are located upstream of exon 1 and exon 2, respectively. 
Differential usage of the promoters has been observed both 
in vitro and in vivo (Jansen et al., 1992). In the rat IGF-I 
gene two promoters are also found in the regions flanking 
exons 1 and 2 (Roberts et al., 1987; Hall et al., 1992). In rats 
class 1 IGF-I mRNA derived from exon 1 is ubiquitous and 
predominant in all tissues studied, but class 2 IGF-I mRNA 
derived from exon 2 is found principally in the liver (Shemer
et al., 1992), and expression of class 2 IGF-I mRNA is more 
GH-sensitive than that of class 1 transcripts (Adamo et al., 
1991). These expression patterns suggest the organ-spe-
cific regulation of transcription.
In mice the presence of two promoters corresponding to 
the two leader exons (exons 1 and 2) has been suggested 
(Kamai et al., 1996); however, functional analysis of 5’-
upstream flanking regions of the IGF-I gene has not been 
undertaken. In the present study the 3’-flanking regions of 
exons 1 and 2 of the mouse IGF-I gene were isolated and 
their sequences were determined to clarify the mouse IGF-
I gene structure. The present study aimed to clarify the dif-
ferential usage of two leader exons of the mouse IGF-I gene 
in the uterus. The uterus shows the next-highest level of 
IGF-I gene expression after the liver in rats and mice 
(Murphy et al., 1987). IGF-I and the type I receptor for IGF-
I (IGF-IR) are expressed in the mouse uterus (Kapur et al., 
1992; Henemyre and Markoff, 1999; Ohtsuki et al., 2005). 
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We investigated the steady-state levels of class 1 and 2 
IGF-I mRNA expression in the uterus at different ages and 
different stages of the estrous cycle to clarify the alternative 
usage of the leader exons. Furthermore, the effects of estra-
diol-17β (E2) on class 1 and class 2 IGF-I mRNA expression 
in the uterus of ovariectomized mice was also studied, since 
estrogen stimulates IGF-I mRNA expression in the uterus 
(Murphy et al., 1987; Kapur et al., 1992; Inoue et al., 2005; 
Murakami et al., 2005; Ohtsuki et al., 2005).
MATERIALS AND METHODS
Animals
Male and female ICR mice (CLEA Japan Inc., Osaka, Japan) 
were used in the present study. They were kept in a temperature–
controlled animal room with free access to CE-7 commercial diet 
(CLEA Japan) and tap water ad libitum. Vaginal-smear sampling 
was conducted daily for at least two weeks. All animal care and 
experiments were performed in accordance with the Guidelines for 
Animal Experimentation of Okayama University, Japan.
RNA preparation and reverse transcription
Total RNA was extracted using the method of Chomczynski 
and Sacchi (1987). Total RNA (2 μg) in a final volume of 20 μl was 
subjected to reverse transcription (RT) reaction using the Super-
script Preamplification System for First Strand cDNA (Gibco BRL, 
Gaithersburg, MD, USA) with an oligo-dT primer, according to the 
manufacturer’s instructions.
Isolation and sequence determination of the 3’ flanking regions 
of mouse IGF-I exons 1 and 2
Mouse class 1 and class 2 IGF-I cDNA fragments obtained 
from the liver were amplified by RT-PCR with a forward primer spe-
cific for each leader exon (exon 1, 5’-ATGGGGAAAATCAGCAGTC-
3’; exon 2, 5’-CTGCCTGTGTAAACGACCCGG-3’) and a reverse 
primer (exon 3-4 junction, 5’-GGCTGCTTTTGTAGGCTTCAGTGG-
3’). Mouse class 1- and class 2-specific primers were designed from 
data in previous reports on mouse exons 1 and 2 (Kamai et al., 
1996) and mouse IGF-I cDNA (Bell et al., 1986). PCR was per-
formed using Takara Taq (Takara, Otsu, Japan) and a Gene Amp 
PCR System 9700 thermal cycler (Applied Biosystems, Branchburg, 
NJ). PCR products were electrophoresed on agarose gels. After 
ethidium bromide staining, class 1 (353 bp) and class 2 (333 bp) 
IGF-I cDNA fragments were excised from the gel and cloned into 
pGEM3Zf (+) (Promega, Madison, WI, USA), and sequenced with a 
BigDye Terminator Cycle Sequencing Kit v. 3.1 (Applied Biosys-
tems, Foster City, CA, USA) using the appropriate PCR primers.
Semi-quantitative analysis of the number of copies of class 1 
and class 2 IGF-I cDNAs
Class 1 and class 2 IGF-I cDNA fragments were amplified by 
PCR with the leader exon-specific primer sets for exon 1 (forward, 
class 1; reverse, exon 3–4 junction) and exon 2 (forward, class 2; 
reverse, exon 3–4 junction), and the PCR products were then elec-
trophoresed on agarose gels. After ethidium bromide staining, class 
1 (353 bp) and class 2 (333 bp) IGF-I cDNA fragments were excised 
from the gel and cloned into pGEM3Zf (+) (Promega). EcoRI-HindIII 
digested fragments were electrophoresed on agarose gels, and the 
fragments were isolated and then quantified by measurement of the 
optical density at 260 nm. The copy number of each cDNA was cal-
culated using the following equation (Overbergh et al., 1999): 1 μg 
of 1000 bp DNA=9.1×1011 molecules.
Serially diluted cDNA templates for class 1-IGF-I and class 2-
IGF-I (class 1, 1.0×108, 1.0×107, 1.0×106, 1.0×105, 1.0×104 copies 
per reaction; class 2, 5.0×107, 5.0×106, 5.0×105, 5.0×104, 5.0×103 
copies per reaction), and the RT products of uteri and liver, were 
amplified by 26 PCR cycles of 20 sec at 95°C, 30 sec at 55°C, and 
40 sec at 72°C, with an additional extension for 10 min at 72°C. 
PCR products were electrophoresed on agarose gels. After ethid-
ium bromide staining, the band intensity was quantified by Kodak 
1D image software (Version 3.6). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) cDNA, amplified using a specific primer 
set (Ohtsuki et al., 2005), was used as an internal control.
Semi-quantitative RT-PCR analysis of class 1 and class 2 IGF-I 
mRNA levels
Class 1 and class 2 IGF-I mRNA fragments were semi-quanti-
fied by RT-PCR with the leader exon-specific primer sets described 
above. PCR conditions were as follows: initial activation of DNA 
polymerase by a 20-sec incubation at 90°C; 30 cycles of 1 min at 
95°C, 1 min at 55°C, and 2 min at 72°C; and an additional extension 
for 10 min at 60°C. Ten-μl aliquots of PCR product of each reaction 
were electrophoresed on 2% agarose gel, stained with ethidium 
bromide, and quantified. Class 1 and class 2 IGF-I mRNA expres-
sion levels were normalized with H2A.X mRNA levels (Ohtsuki et 
al., 2005). In a preliminary study we had confirmed that the PCR 
products of both class 1 and class 2 IGF-I mRNA increased linearly 
from 22 to 26 cycles (liver), from 24 to 28 cycles (uterus) and from 
26 to 28 cycles (kidney).
Ovariectomy and estrogen treatment
Adult female mice were ovariectomized at 8 weeks of age 
under light ether anesthesia. Seven days later, they were subcuta-
neously injected with estradiol-17β (E2, Sigma-Aldrich, St. Louis, 
MO, USA; E2 was dissolved in sesame oil) at doses of 25 and 250 
ng/mouse (0.1 ml) or with the same volume of sesame oil. At 0, 3, 
6, 12, 24, 48, 72 and 96 hr after E2 treatment, uteri were collected 
for RNA extraction.
Statistics
Data are presented as the mean±standard error of the mean 
(SEM) and were analyzed by analysis of variance with the post-hoc 
Bonferroni/Dunn test.
RESULTS
Comparison of nucleotide sequences of the 3’-flanking 
regions of exons 1 and 2 of the mouse and rat IGF-I 
genes
The DNA sequences of mouse and rat IGF-1 exons 1 
and 2 are aligned in Fig. 1A and 1B. Exon 1 and exon 2 
showed high degree of identity between the mouse and rat 
IGF-I genes. The 3’-flanking region of mouse IGF-I exon 1 
analyzed shared 100% identity with that of rat IGF-I exon 1. 
The 3’-flanking region of mouse IGF-I exon 2 analyzed 
shared 91.4% identity with that of rat IGF-I exon 2.
Expression profiles of class 1 and class 2 IGF-I mRNA in 
the uterus and liver
Using a known number of copies of class 1 and class 2 
IGF-I cDNA as templates in PCR, class 1 (derived from exon 
1) and class 2 (derived from exon 2) IGF-I mRNA levels 
were analyzed in adult female mice. The PCR products of 
each class of IGF-I cDNA increased in accordance with the 
increase of template cDNAs under the PCR conditions used 
(Fig. 2A). Class 1 and class 2 IGF-I mRNAs were detected 
in the uterus (U) and liver (L) by RT-PCR (Fig. 2B). Both 
class 1 and class 2 IGF-I mRNA levels were higher in the 
liver than in the uterus. The amount of class 1 PCR products 
generated from the uterine and liver samples was more than 
the amount of PCR products generated from the class 1 
templates (1.0×106 copies), and the amount of class 2 PCR 
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products generated from the uterine and liver samples was 
less than the PCR products generated from the class 2 tem-
plates (5.0×105 copies). The numbers of copies of class 1 
and class 2 IGF-I cDNAs were determined: in the uterus, 
class 1 had 1.8×106 copies and class 2 had 3.2×105 copies; 
in the liver, class 1 had 3.6×106 copies and class 2 had 
3.8×105 copies.
Changes in class 1 and class 2 IGF-I mRNA levels during 
the estrous cycle
To determine changes in class 1 and class 2 IGF-I 
expression during the estrous cycle in the uterus, liver and 
kidney, class 1 and class 2 IGF-I mRNA levels were meas-
ured in 60-day-old female mice by RT-PCR analysis (Fig. 3). 
Class 1 and class 2 IGF-I mRNA levels on the first day of 
diestrus (D1) were defined as 1. In the uterus, class 1 and 
class 2 IGF-I mRNA levels changed markedly during the 
estrous cycle. The highest levels of both types of IGF-I 
mRNA were detected at proestrus. No significant changes in 
class 1 and class 2 IGF-I mRNA levels were detected in the 
liver and kidney during the estrous cycle.
Fig. 1. DNA sequences of mouse and rat IGF-1 exon 1 (A) and exon 2 (B). Identical residues between the mouse and rat sequences are indi-
cated by asterisks; deletions are indicated by a dash. Exons 1 and 2 of the mouse IGF-I gene show a high degree of identity with those of the 
rat IGF-I gene.
Fig. 2. RT-PCR analysis of IGF-I mRNA variant expression in the mouse uterus (U) and liver (L) using exon 1- and exon 2-specific primer 
pairs (see Materials and Methods). (A) PCR amplification of serially diluted class 1 and class 2 IGF-I cDNA. Serially diluted cDNA templates for 
class 1 (1.0×108, 1.0×107, 1.0×106, 1.0×105, 1.0×104 copies per reaction) and class 2 (5.0×107, 5.0×106, 5.0×105, 5.0×104, 5.0×103 copies per 
reaction) IGF-I were amplified by 26 PCR cycles (see Materials and Methods). (B) Comparison of class 1 and class 2 IGF-I mRNA expression 
in the uterus (U) and liver (L) by RT-PCR. Samples from the uterus and liver and cDNA samples (class 1, 1.0×106 copies; class 2, 5.0×105 cop-
ies) were amplified by PCR under the same conditions as for (A). GAPDH cDNA was used as an internal control. A 100-bp ladder was used as 
a molecular size marker (M). The number to the left depicts the size of products (bp).
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Effect of E2 on class 1 and class 2 IGF-I mRNA expres-
sion in the uterus of ovariectomized mice
The time course of the effect of E2 on uterine class 1 
and class 2 IGF-I mRNA levels was studied by RT-PCR 
analysis (Fig. 4). E2 treatment (25 and 250 ng) increased 
class 1 IGF-I mRNA levels markedly from 6 hr to 12 hr after 
E2 injection (Fig. 4A); in contrast, class 2 IGF-I mRNA levels 
changed at 6 hr (Fig. 4B). The highest levels of class 1 IGF-
I mRNA were detected at 6 hr irrespective of the dose used. 
At 6 hr, 13-fold and 20-fold increases in class 1 IGF-I mRNA 
levels were detected with E2 treatment at 25 and 250 ng, 
respectively, while a fourfold increase in class 2 IGF-I 
Fig. 3. Changes in class 1 and class 2 IGF-I mRNA expression in 
the uterus (A), liver (B), and kidney (C) during the estrous cycle. 
RNA samples were collected at proestrus (P), estrus (E), the first 
day of diestrus (D1), and the second day of diestrus (D2), and class 
1 and class 2 IGF-I mRNA levels were determined by RT-PCR anal-
ysis, as described in Materials and Methods. Class 1 IGF-I mRNA 
levels are expressed by open bars, and class 2 by closed bars. 
Each mRNA level was normalized relative to the H2A.X mRNA 
level. The mRNA levels at D1 were defined as 1. Data are 
expressed as the mean±SEM (n=5). * P<0.05, significantly different 
from the level at D1.
Fig. 4. Effect of E2 on class 1 (A) and class 2 (B) IGF-I mRNA 
expression in the uteri of ovariectomized mice. Ovariectomized mice 
were given a single injection of E2 (25 or 250 ng/mouse) or the vehi-
cle, which was sesame oil. Class 1 and class 2 IGF-I mRNA levels 
were determined by RT-PCR analysis, as described in Materials 
and Methods. IGF-I mRNA levels were normalized relative to the 
H2A.X mRNA level. The mRNA level at 0 hr was defined as 1. Data 
are expressed as the mean±SEM (n=3). * P<0.05, ** P<0.01, signif-
icantly different from the vehicle-treated control; # P<0.05, ## 
P<0.01, significantly different from the level at 25 ng E2-treated.
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mRNA levels was detected with E2 treatment at 250 ng.
DISCUSSION
Mouse IGF-I mRNAs are classified based on the usage 
of leader exons 1 and 2. Class 1 IGF-I mRNA is transcribed 
from exon 1, and class 2 from exon 2. Expression of the two 
leader exons of the mouse IGF-I gene was detected in the 
uterus, liver and kidney, as reported for human and rat IGF-
I genes (Lowe et al., 1987; Adamo et al., 1989; Shemer et 
al., 1992). We semi-quantitatively analyzed IGF-I mRNA 
expression and found that class 1 IGF-I mRNA was the 
major transcript type and showed higher expression than 
class 2; this is in agreement with previous reports (Lowe et 
al., 1987; Adamo et al., 1989, 1991). The presence of mul-
tiple leader exons and differences in IGF-I mRNA levels 
transcribed suggest the presence of distinct promoters con-
trolling IGF-I gene transcription, which have already been 
reported for human and rat IGF-I genes (Roberts et al., 
1987; Jansen et al., 1992; Wang et al., 1997). The physio-
logical significance of the presence of multiple leader exons, 
and probably multiple promoters, resulting in the production 
of multiple types of transcripts of the IGF-I gene is unclear. 
However, the presence of multiple promoters for IGF-I gene 
transcription appears to be favorable for the organ-specific 
and fine control of IGF-I synthesis under various conditions, 
since IGF-I proteins are expressed in various cell types and 
have unique roles in the cells expressing them.
Two promoters of the mouse IGF-I gene are thought to 
be located in the 5’- flanking regions proximal to exons 1 
and 2, but these two putative promoters have not yet been 
characterized (Kamai et al., 1996). Usage of the leader 
exons was analyzed in mouse uterus, liver and kidney dur-
ing the estrous cycle. In the uterus, class 1 and class 2 IGF-
I mRNA expression changed markedly during the estrous 
cycle, with the highest levels at proestrus. There was a five-
fold increase in class 1 expression and a fourfold increase 
in class 2 IGF-I mRNA expression in proestrus compared to 
the first day of diestrus, while in the liver and kidney there 
were no significant changes in class 1 or class 2 IGF-I 
mRNA expression during the estrous cycle.
Estrogen is well known to stimulate IGF-I gene expres-
sion in the uterus (Murphy et al., 1987; Kapur et al., 1992; 
Inoue et al., 2005; Murakami et al., 2005), and we also 
showed the stimulatory role of estrogen in the expression of 
both types of IGF-I mRNAs in the mouse uterus. These find-
ings indicate that the regulation of uterine class 1 and class 
2 IGF-I mRNA expression is estrous cycle-dependent, and 
it is highly probable that the main regulator is estrogen, 
since blood estrogen levels are high during proestrus (Smith
et al., 1975). In contrast, we did not detect changes in IGF-
I mRNA levels in the liver or kidney during the estrous cycle. 
In addition, hepatic IGF-I expression is not stimulated by 
estrogen treatment (Murphy and Friesen, 1988). The differ-
ence in patterns of IGF-I mRNA expression during the 
estrous cycle between the uterus and the other organs is not 
due to differences in estrogen receptor expression, since 
estrogen receptor mRNA was detected in the uterus, liver 
and kidney by RT-PCR in mice (Ohtsuki et al., 2005; 
Manabe et al., unpublished observation). The organ-specific 
regulatory mechanism of IGF-I gene expression, particularly 
under estrogen stimulation, needs to be studied.
Estrogen treatment increased both class 1 and class 2 
IGF-I mRNA levels in the uterus of ovariectomized mice, 
which is in agreement with previous studies carried out in 
the rat uterus (Carlsson and Billig, 1991; Klotz et al., 2000), 
but class 1 IGF-I mRNA expression increased more in 
response to estrogen treatment than class 2 expression. 
These findings indicate that estrogen activates two putative 
promoters of the IGF-I gene in uterine cells, and that a pro-
moter involved in transcription of class 1 IGF-I mRNA is 
more responsive to estrogen. However, during the estrous 
cycle, both class 1 and class 2 IGF-I mRNA levels in the 
uterus changed in a similar manner. IGF-I gene transcription 
is regulated by multiple factors, and among them progester-
one is one of the main regulators and enhances estrogen-
induced IGF-I mRNA expression (Kapur et al., 1992). 
Changes in IGF-I mRNA levels in the uterus during the 
estrous cycle may be regulated by not only estrogen, but 
also progesterone. It is highly probable that combined 
effects of estrogen and progesterone enhance the promoter 
activity involved in class 2 IGF-I mRNA expression in the 
uterus.
In chickens, the IGF-I gene is stimulated by estrogen 
through the AP-1 motif located in the promoter region 
(Umayahara et al., 1994). In rats, CCAAT enhancer-binding 
protein δ (C/EBPδ) is a critical regulator of IGF-I gene tran-
scription (Umayahara et al., 1999), and estrogen decreases 
IGF-I gene expression in osteoblasts through the cAMP 
pathway with C/EBPδ (Chang et al., 2005). However, the 
mechanism of estrogen-induced IGF-I gene expression in 
the uterus remains unclear, and further study concerning the 
regulatory mechanism of uterine IGF-I gene expression is 
needed.
IGF-I is expressed in the endometrial luminal and glan-
dular epithelia, stroma and myometrium in rats and mice 
(Murphy et al., 1987; Ghahary et al., 1990; Kapur et al., 
1992). Enhanced IGF-I mRNA expression of both classes in 
the uterus at proestrus and estrus leads to the production of 
IGF-I protein. IGF-I stimulates DNA synthesis and the prolif-
eration of uterine epithelial cells in rats and mice (Beck and 
Garner, 1992; Shiraga et al., 1997). Proliferation of uterine 
epithelial cells induced by estrogen is mediated by polypep-
tide growth factors synthesized in uterine tissues (Cooke et 
al., 1997). These findings suggest that IGF-I is a candidate 
as an estrogen-induced growth factor that regulates the pro-
liferation of endometrial epithelial cells. Adesanya et al.
(1999) demonstrated that IGF-I is involved in the G2 pro-
gression of mouse uterine cells under estrogen stimulation, 
although IGF-I is generally considered to act in the G1 
phase as a G1-progression factor (Pestell et al., 1999).
We recently found alternative splicing of IGF-I mRNA in 
mice, generating two variants of IGF-I mRNA, IGF-IA and 
IGF-IB (Ohtsuki et al., 2005). Both IGF-IA and IGF-IB 
mRNAs are generated from each of class 1 and class 2 IGF-
I mRNA, resulting in the production of four variants of IGF-I 
mRNAs. Both IGF-IA and IGF-IB mRNA levels in ovariecto-
mized mouse uteri were elevated by E2 treatment, which is 
in agreement with a previous rat uterus study (Klotz et al., 
2000). The relative increase in class 1 IGF-I mRNA levels 
with estrogen was higher than that in class 2 levels. There-
fore, estrogen may stimulate the alternative usage and splic-
ing that generates class 1 IGF-I mRNA variants. Interest-
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ingly, an exonic splicing enhancer is located in human 
alternative exon 5 of the IGF-I gene, and serine-arginine 
protein splicing factor-2/alternative splicing factor promotes 
the splicing of human IGF-I mRNA (Smith et al., 2002). If a 
similar system operates in the mouse uterus, estrogen may 
be involved in the activation of the alternative splicing-factor 
system.
In conclusion, the present study revealed that two leader 
exons of mouse IGF-I gene operate in the uterus, liver and 
kidney, and that there are probably two promoters for IGF-I 
gene expression. Estrous cycle-dependent IGF-I gene 
expression was found in the uterus alone. Estrogen 
increased uterine IGF-I mRNA levels of both classes. The 
usage of the leader exons of the mouse IGF-I gene was 
controlled in an organ-specific and hormone (estrogen)-
dependent manner.
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